Dopamine Agonists Market Report 2025

The dopamine agonists market size has grown strongly in recent years. It will grow from $2.57 billion in 2024 to $2.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increasing incidence of Parkinson’s disease, rising diagnosis of restless legs syndrome (RLS), expansion of reimbursement coverage, growing CNS disorder research funding, and increasing healthcare awareness.

The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to $3.61 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the rising prevalence of neurological disorders, aging global population, increase in research and clinical trials, expansion of combination therapies, rising awareness, and diagnosis rates. Major trends in the forecast period include personalized medicine and genetic profiling, wearable drug delivery systems, AI and machine learning in drug development, extended-release formulations, and nanotechnology for drug delivery.

The forecast of 7.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of dopamine agonist medications sourced from Israel and Germany, thereby prolonging Parkinson's disease treatment timelines and elevating neurology care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of neurological disorders is expected to significantly drive the growth of the dopamine agonist market. Neurological disorders, which impact the brain, spine, or nerves, cause issues related to movement, cognition, and behavior. This increase in prevalence is largely due to longer life expectancies, as conditions such as Alzheimer's and Parkinson's become more common with age. Dopamine agonists are used to treat disorders such as Parkinson's disease by stimulating dopamine receptors in the brain, helping to enhance motor control and alleviate symptoms. For example, the Alzheimer's Disease Facts and Figures report from the Alzheimer's Association, a US-based nonprofit focused on Alzheimer's care, support, and research, indicates that in 2022, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia, a number projected to rise to 6.9 million by 2024. As a result, the growing prevalence of neurological disorders will continue to drive the expansion of the dopamine agonist market.

Leading companies in the dopamine agonist market are focusing on innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more tailored treatment solutions for neurological disorders. Flexible-dose monotherapy involves a single drug with an adjustable dosage, allowing healthcare providers to customize the treatment based on the patient's unique needs and responses. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive results from its Phase 3 TEMPO-2 trial, where investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), showed significant improvements in motor function among early Parkinson's disease patients. The trial met its primary goal with a substantial reduction in MDS-UPDRS Parts II and III scores and achieved important secondary objectives, indicating meaningful improvements in daily motor activities. Tavapadon is the first D1/D5 partial agonist being investigated for once-daily Parkinson's treatment.

In August 2024, AbbVie, a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. This strategic acquisition allows AbbVie to enhance its neuroscience portfolio by gaining access to Cerevel's innovative pipeline of treatments targeting psychiatric and neurological disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for neurological and psychiatric conditions.

Major players in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG.

North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dopamine agonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dopamine agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The dopamine agonist market research report is one of a series of new reports that provides dopamine agonist market statistics, including the dopamine agonist industry global market size, regional shares, competitors with the dopamine agonist market share, detailed dopamine agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the dopamine agonist industry. This dopamine agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Dopamine agonists are medications that activate dopamine receptors in the brain, mimicking the effects of natural dopamine. These medications are commonly used to manage disorders caused by low dopamine activity or impaired dopamine signaling.

The main types of dopamine agonists are ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are derived from ergot alkaloids and work by activating dopamine receptors in the brain to help manage neurological and hormonal conditions. These medications are available in various forms, including oral, parenteral (injectable), and transdermal patches. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. Ergot-based dopamine agonists are commonly used in the treatment of conditions such as Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. Key end users include hospitals, clinics, and home care settings.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.